Plasminogen Activator Inhibitor-1 Is Involved in Streptozotocin-Induced Bone Loss in Female Mice

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 1.
FIG. 1.

Effects of streptozotocin treatment on circulating PAI-1 levels and PAI-1 expression in both sexes of WT mice. Growth curve during experiments (A) in control and streptozotocin-treated male and female of PAI-1 WT mice. Results are expressed as means ± SEM. **P < 0.01 vs. each control group (n = 5 in each group). Blood glucose (B) and plasma PAI-1 levels (C) in control and streptozotocin-treated male and female WT mice. Results are expressed as means ± SEM. *P < 0.05, **P < 0.01 (n = 5 in each group). Levels of PAI-1 mRNA in bone (tibia), liver, kidney, lung, heart, muscle, and spleen (D) in control and streptozotocin-treated male and female WT mice. Results are expressed relative to β-actin mRNA values and expressed as means ± SEM. *P < 0.05, **P < 0.01 (n = 5 in each group). Cont, control; d, day(s); F, female; M, male; STZ, streptozotocin.

This Article

  1. Diabetes vol. 62 no. 9 3170-3179